Clinical Trials Browser

Phase 2 × Breast Neoplasms × abemaciclib × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07428018 2026-03-05

VIOLET

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT07292207 2025-12-18

ARCHE

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04305834 2025-09-24

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Phase 2 Recruiting

Breast Neoplasms

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Phase 2 Recruiting

Breast Neoplasms

NCT04523857 2025-04-04

ABBY

Phase 2 Recruiting

Breast Neoplasms

NCT06259929 2025-02-18

Neo-AGILE

Phase 2 Recruiting

Breast Neoplasms

NCT04432454 2025-02-13

ELAINEII

Phase 2 Completed

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

Phase 2 Not yet recruiting

Breast Neoplasms

NCT03703466 2024-04-02

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Phase 2 Completed

72 enrolled 19 charts

Breast Neoplasms

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

Phase 2 Recruiting

Breast Neoplasms

NCT02441946 2020-06-17

neoMONARCH

Phase 2 Completed

224 enrolled 20 charts

Breast Neoplasms

NCT02102490 2020-01-21

MONARCH 1

Phase 2 Completed

132 enrolled 17 charts 1 FDA

Breast Neoplasms